Last Updated: November 16, 2026

Details for Patent: 8,147,809

« Back to Dashboard


Which drugs does patent 8,147,809 protect, and when does it expire?

Patent 8,147,809 protects SOFDRA and is included in one NDA.

This patent has ten patent family members in six countries.

Summary for Patent: 8,147,809
Title:Soft anticholinergic esters
Abstract:Soft anticholinergic esters of the formulas: wherein R1 and R2 are both phenyl or one of R1 and R2 is phenyl and the other is cyclopentyl; R is C1-C8 alkyl, straight or branched chain; and X− is an anion with a single negative charge; and wherein each asterisk marks a chiral center; said compound having the R, S or RS stereoisomeric configuration at each chiral center unless specified otherwise, or being a mixture thereof.
Inventor(s):Nicholas S. Bodor
Assignee: Bodor Laboratories Inc
Application Number:US12/494,367
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent landscape, scope, and claims:

United States Patent 8,147,809: Claim Scope, Patent Landscape, Exclusivity and Generic-Entry Risk

U.S. Patent No. 8,147,809 covers a narrow class of quaternary pyrrolidinium bromide anticholinergic compounds, stereoisomeric forms of those compounds, and pharmaceutical compositions containing them. The strongest protection is compound-specific: a product containing one of the expressly listed salts may fall within claims 1-3 even if it is formulated differently. Claims 4-6 extend protection to pharmaceutical compositions but are secondary to the underlying compound claims.

The claims do not, by themselves, establish an FDA-approved product, an Orange Book listing, an approved drug name, or a current commercial product. The patent text supports a chemical and formulation analysis, but a definitive expiration date, terminal disclaimer analysis, continuation-family review, Orange Book status, and litigation assessment require the complete USPTO prosecution and family records.

What compounds does U.S. Patent 8,147,809 protect?

The patent protects anticholinergic pyrrolidinium bromide compounds built around four structural elements:

  1. A substituted pyrrolidinium ring.
  2. An N-methyl group.
  3. An N-linked methoxycarbonylmethyl or ethoxycarbonylmethyl substituent.
  4. An esterified 2-cyclopentyl-2-phenyl-2-hydroxyacetic acid moiety.

The claimed compounds contain one or more stereogenic centers. The claims expressly cover individual stereoisomers and, in several instances, mixtures of stereoisomers.

Structural feature Claim treatment
Core ring 1-methylpyrrolidinium
Permanent charge Quaternary ammonium cation
Counterion Bromide
N-substituent Methoxycarbonylmethyl or ethoxycarbonylmethyl
Ester side chain 2-cyclopentyl-2-phenyl-2-hydroxyacetoxy
Stereochemistry Racemates, mixtures and specified stereoisomers
Pharmacology Anticholinergic activity
Dosage-form protection Pharmaceutical compositions with a pharmaceutically acceptable carrier

The use of a quaternary pyrrolidinium center is significant. Unlike a neutral or readily protonatable tertiary amine, the claimed compounds carry a permanent positive charge. That structural feature can affect receptor distribution, absorption, inhalation delivery, systemic exposure and formulation strategy. A competitor cannot avoid the claims merely by changing a dosage form if the active chemical compound remains within the claimed structure.

How broad is claim 1?

Claim 1 is the principal genus claim. It covers a compound defined by a formula in which R is methyl or ethyl, with the indicated stereochemical configurations at each marked chiral center.

Its scope has three important dimensions.

R-group coverage

The claim covers two alternatives:

  • R = methyl, corresponding to the methoxycarbonylmethyl derivative.
  • R = ethyl, corresponding to the ethoxycarbonylmethyl derivative.

A compound with a propyl, isopropyl or other homologous group would not literally satisfy the R limitation as stated. Such a compound could raise a doctrine-of-equivalents issue, but that would depend on prosecution history, structural differences and the specific accused product.

Stereochemical coverage

Claim 1 is materially broader than a single enantiomer claim. It covers compounds having the R, S or RS configuration at each marked chiral center, or mixtures of those configurations. This language potentially reaches:

  • Individual enantiomers.
  • Diastereomers.
  • Racemic mixtures.
  • Mixtures containing multiple stereoisomeric forms.

The claim therefore reduces a common design-around route. A competitor cannot necessarily avoid claim 1 by using a different stereochemical form of the same constitutional structure.

Salt and charge-state limitations

The claim language in claims 2 and 3 expressly identifies the bromide salts. Claim 1, as supplied, refers to a formula rather than repeating the full chemical name. The applicable Markush and structural limitations must be read from the issued patent drawings and specification. On the supplied claim text, a materially different counterion should not automatically be assumed to fall within the claim.

A chloride, iodide, methanesulfonate or fumarate salt may create a non-infringement position if the bromide counterion is a claim limitation. The strength of that position depends on whether the issued claim defines the counterion expressly, incorporates it through the depicted formula, or covers the cation independently.

What compounds are expressly listed in claims 2 and 3?

Claims 2 and 3 narrow the invention to named compounds and selected stereochemical forms.

Claim Subject matter Relative breadth
1 Formula-based genus with methyl or ethyl R groups and stereochemical alternatives Broadest
2 Thirteen expressly identified compounds and stereochemical forms Narrower, but chemically specific
3 Four compounds, including non-resolved and 2R forms Narrower than claim 2
4 Composition containing a claim 1 compound Composition claim
5 Composition containing a claim 3 compound Narrow composition claim
6 Composition containing a claim 2 compound Narrow composition claim

Claims 2 and 3 are compositionally important because they create fallback positions if claim 1 is rejected or invalidated. A challenger may attack the genus claim for written-description, enablement, anticipation or obviousness reasons while leaving one or more individually claimed stereoisomers intact.

The expressly listed structures include both methyl and ethyl ester variants. Claim 2 also identifies multiple configurations at the 2-position and at the additional stereocenters designated in the claim. The presence of separate stereochemical limitations suggests that the patent family placed commercial or pharmacological value on particular isomers rather than treating all forms as interchangeable.

What pharmaceutical compositions are protected?

Claims 4-6 cover pharmaceutical compositions containing an anticholinergically effective amount of a claimed compound and a non-toxic pharmaceutically acceptable carrier.

These claims have two principal limitations:

  1. The active ingredient must be a compound falling within claim 1, claim 2 or claim 3.
  2. The amount must be anticholinergically effective.

The claims do not, based on the supplied text, require a particular:

  • Inhaler.
  • Nebulizer.
  • Dry-powder carrier.
  • Metered-dose device.
  • Tablet.
  • Capsule.
  • Injectable vehicle.
  • Particle size.
  • Excipient.
  • Dose strength.
  • Release profile.
  • Treatment population.
  • Disease indication.

This makes the composition claims potentially broad across dosage forms, but their enforceability depends on proving that the accused composition contains a claimed compound in an effective amount. A formulation patent covering particle engineering, device architecture, excipient ratios or a specific inhaled dose would be separate from these basic composition claims.

Does the patent protect methods of treatment?

The supplied claims do not include a method-of-treatment claim. They are directed to:

  • Compounds.
  • Named stereoisomers.
  • Pharmaceutical compositions.

That distinction matters in the United States. A product may infringe a compound or composition claim regardless of the therapeutic indication appearing on its label. Conversely, a competitor might avoid a method-of-use patent by changing the indication or dosing regimen, but that strategy does not avoid a structurally applicable compound claim.

The absence of an identified method-of-use claim in the supplied claims also means the patent does not, on this record, provide distinct protection for:

  • Chronic obstructive pulmonary disease.
  • Asthma.
  • Bronchospasm.
  • Perioperative secretion control.
  • A specific inhaled dosing schedule.
  • Combination therapy with a beta-agonist or inhaled corticosteroid.

Those subjects may be covered by other patents in the family or by unrelated patents, but they are not established by claims 1-6.

How strong is the patent estate based on the issued claims?

The patent has a mixed but commercially meaningful claim structure.

Strong points

The compound claims have several characteristics that can support enforcement:

  • The core scaffold is structurally defined.
  • Both methyl and ethyl variants are covered.
  • Multiple stereoisomers and mixtures are addressed.
  • The permanent quaternary ammonium center narrows the chemical space.
  • The named-compound claims provide fallback protection.
  • The composition claims can reach products using the claimed active ingredient in different formulations.

A generic or follow-on company that uses the same active moiety would face a substantial chemical infringement risk if the product contains the claimed bromide compound or converts to that compound during manufacture or administration.

Limiting points

The patent does not appear, from the supplied claims, to cover every anticholinergic compound with a related pharmacophore. Design-around opportunities may include:

  • Replacing the bromide counterion, if the counterion is limiting.
  • Removing or changing the N-linked methoxycarbonylmethyl or ethoxycarbonylmethyl group.
  • Modifying the cyclopentyl substituent.
  • Replacing the phenyl group.
  • Changing the pyrrolidinium ring.
  • Using a different ester linkage.
  • Selecting a structurally distinct prodrug that does not contain the claimed compound.

A design-around must be assessed against the complete claim language, not only the chemical name. A prodrug or alternate salt can still create infringement risk if the claimed compound is made during synthesis, exists in the administered product, or is generated in vivo under an applicable infringement theory.

What is the likely patent expiration date?

U.S. Patent No. 8,147,809 issued on April 3, 2012. The controlling term is generally 20 years from the earliest effective nonprovisional U.S. filing date or applicable international filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers and statutory exceptions under 35 U.S.C. §§ 154 and 156.

The issued patent number and claims alone do not establish the final enforceable expiration date. A reliable term calculation must account for:

Term issue Potential effect
Earliest priority claim Determines the relevant patent-family chronology
PCT filing May provide the effective international filing date
USPTO patent-term adjustment Can extend the nominal term
Terminal disclaimer Can shorten the term to match another patent
Patent-term extension May extend protection for regulatory review
Patent-term disclaimer or disclaimer events Can alter enforceability
Continuation or divisional practice May create related patents with later expiration dates

The key commercial point is that U.S. 8,147,809 should not be treated as the entire exclusivity position. A product may remain protected after this patent expires through later-filed patents covering a specific stereoisomer, formulation, inhaler, dosage regimen, manufacturing process or combination product.

What is the Orange Book status of U.S. Patent 8,147,809?

The supplied claims do not identify an FDA-approved product or application number. The patent therefore cannot be assigned an Orange Book status solely from the claim language.

For an approved small-molecule drug, Orange Book relevance depends on whether the patent is submitted by the NDA holder and accepted by FDA as claiming:

  • The drug substance.
  • The drug product.
  • A method of using the drug.

FDA does not list every patent that may theoretically read on an approved product. Orange Book listing is tied to the statutory patent-submission framework in 21 U.S.C. § 355(b)(1) and FDA regulations.

If no approved product is associated with the claimed compounds, there would be no product-specific Orange Book listing and no Hatch-Waxman Paragraph IV dispute based on this patent. If an approved product is associated with the compounds, the listing status must be checked against the current FDA Orange Book and the relevant NDA patent-certification history.[1]

Are there Paragraph IV challenges or generic litigation?

The supplied information does not establish a Paragraph IV certification, Abbreviated New Drug Application, district-court action, or settlement involving U.S. 8,147,809.

A Paragraph IV case requires an ANDA applicant to certify that a listed patent is invalid, unenforceable or will not be infringed. The resulting litigation ordinarily depends on four facts:

  1. The patent is listed in the Orange Book.
  2. An ANDA applicant makes a Paragraph IV certification.
  3. The NDA holder receives the certification notice.
  4. The NDA holder files an action within the statutory period.

A patent that is not Orange Book-listed can still be asserted in ordinary patent litigation, but it does not automatically create the Hatch-Waxman 30-month stay associated with a listed patent.

What manufacturing and intellectual-property barriers does the patent create?

The patent creates a direct barrier where a competing manufacturer must synthesize one of the claimed compounds. Relevant risk points include:

  • Preparation of the quaternary pyrrolidinium intermediate.
  • Formation of the hydroxyacetate ester.
  • Control of regioisomers and stereoisomers.
  • Resolution or enrichment of the specified configurations.
  • Isolation of the bromide salt.
  • Conversion into a pharmaceutical composition.
  • In-process or final-product testing showing the claimed compound.

A supplier may avoid literal infringement by using a different synthetic route, but process changes do not avoid a claim directed to the final compound. Conversely, a process patent could create separate manufacturing risk even when the final active ingredient falls outside U.S. 8,147,809.

How does this patent compare with formulation and method-of-use patents?

U.S. 8,147,809 is primarily a chemical compound patent.

Patent type Primary protection Relevance to generic entry
Compound patent Active chemical structure and stereochemistry Usually the highest direct barrier
Salt or polymorph patent Solid form or counterion May block a specific commercial presentation
Formulation patent Excipients, particle size, release or stability Can be designed around more readily
Device patent Inhaler or delivery mechanism Relevant only to the device configuration
Method-of-use patent Indication or dosing regimen May be addressed through a skinny-label strategy
Manufacturing patent Synthetic route or purification Can require process redesign

A competitor that avoids a formulation or use patent may still infringe the compound claims. The reverse is also true: expiration or invalidity of the compound patent does not eliminate separate formulation, device or process patents.

What generic launch scenarios exist?

Launch after complete patent expiry

This is the lowest-risk scenario if no continuation, formulation, method-of-use or regulatory exclusivity remains. The entrant would still need to address applicable FDA requirements and any other enforceable patents.

Paragraph IV launch

If the patent is Orange Book-listed, an ANDA applicant could challenge validity, enforceability or infringement. The commercial risk would include litigation, a possible 30-month stay and potential damages for an at-risk launch.

Non-infringing design-around

A competitor could develop a structurally distinct anticholinergic compound, alternate salt, different ring system or different ester architecture. This route carries development and regulatory risk because pharmacology, delivery and clinical comparability may change.

Authorized or licensed entry

A license, covenant not to sue or settlement could permit earlier market entry. No such agreement is established by the supplied claims.

What geographic coverage does the patent provide?

U.S. Patent 8,147,809 provides rights only in the United States. Foreign counterparts, if any, must be evaluated separately by jurisdiction. Important differences include:

  • European patent validation and national post-grant proceedings.
  • Patent-term calculations.
  • Supplementary protection certificates.
  • Patent-linkage rules.
  • Orange Book equivalents.
  • Generic approval procedures.
  • Availability of opposition or invalidation actions.

A U.S. expiration or invalidity event does not automatically affect counterpart patents in Europe, Canada, Japan, China or other markets.

Key Takeaways

  • U.S. 8,147,809 is directed to quaternary pyrrolidinium bromide anticholinergic compounds and compositions containing them.
  • Claim 1 is the principal genus claim and covers methyl and ethyl N-substituent variants with broad stereochemical coverage.
  • Claims 2 and 3 provide narrower protection for expressly named compounds and stereoisomers.
  • Claims 4-6 extend protection to pharmaceutical compositions, but no specific dosage form, device, indication or dosing schedule appears in the supplied claims.
  • The patent is stronger against use of the same active chemical compound than against structurally distinct follow-on compounds.
  • The claims do not establish an Orange Book listing, FDA approval, Paragraph IV challenge, litigation, settlement or licensing deal.
  • The final expiration date cannot be determined from the claims alone because patent-term adjustment, terminal disclaimer and extension records control.
  • Later patents covering formulations, devices, methods of use, manufacturing processes or specific stereoisomers may create additional exclusivity after this patent’s term.

FAQs

Does changing bromide to chloride avoid U.S. Patent 8,147,809?

Not necessarily. If the issued claim requires the bromide salt, a different counterion may support a non-infringement position. The complete claim language and prosecution history determine whether the cation, salt or both are required.

Does using only one enantiomer avoid the patent?

Usually not if the selected enantiomer is one of the stereochemical configurations expressly covered. Claim 1 also covers specified stereoisomers and mixtures.

Can a different inhaler avoid the patent?

A different inhaler may avoid a device-specific patent, but it does not avoid a compound claim if the inhaler contains a claimed active ingredient.

Is a pharmaceutical composition claim limited to inhaled products?

Not on the supplied language. Claims 4-6 refer generally to a pharmaceutical composition and a pharmaceutically acceptable carrier. They do not identify an inhaled dosage form.

Can a generic manufacturer challenge this patent without filing Paragraph IV?

Yes. A company can pursue non-infringement or invalidity strategies outside the ANDA Paragraph IV framework, although the procedural and commercial consequences differ from a Hatch-Waxman challenge.

References

  1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
  2. U.S. Patent No. 8,147,809. (2012). Claims 1-6. United States Patent and Trademark Office.
  3. United States Code, 21 U.S.C. § 355.
  4. United States Code, 35 U.S.C. §§ 154, 156.
  5. United States Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, patent term and patentability provisions.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,147,809

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Botanix Sb SOFDRA sofpironium bromide GEL, METERED;TOPICAL 217347-001 Jun 18, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.